LitAlert ~~ GeneLit.com

    • Total and out-of-pocket costs for PARP inhibitors among insured ovarian cancer patients.
    • Liang MI, Chen L, Hershman DL, Hillyer GC, Huh WK, Guyton A, Wright JD.
    • Gynecol Oncol. 2020 Dec 27:S0090-8258(20)34218-9. doi: 10.1016/j.ygyno.2020.12.015. Epub ahead of print.
    • Characterizing TP53 mutations in ovarian carcinomas with and without concurrent BRCA1 or BRCA2 mutations.
    • Ghezelayagh TS, Pennington KP, Norquist BM, Khasnavis N, Radke MR, Kilgore MR, Garcia RL, Lee M, Katz R, Leslie KK, Risques RA, Swisher EM.
    • Gynecol Oncol. 2020 Dec 26:S0090-8258(20)34178-0. doi: 10.1016/j.ygyno.2020.12.007. Epub ahead of print.
    • Motivations and barriers to pursue cancer genomic testing: a systematic review.
    • Smith-Uffen M, Bartley N, Davies G, Best M.
    • Patient Educ Couns. 2020 Dec 25:S0738-3991(20)306881. doi: 10.1016/j.pec.2020.12.024. Epub ahead of print.
    • Review
    • Targeting immunosuppressive macrophages overcomes PARP inhibitor resistance in BRCA1-associated triple-negative breast cancer.
    • Mehta AK, Cheney EM, Hartl CA, Pantelidou C, Oliwa M, Castrillon JA, Lin JR, Hurst KE, de Oliveira Taveira M, Johnson NT, Oldham WM, Kalocsay M, Berberich MJ, Boswell SA, Kothari A, Johnson S, Dillon DA, Lipschitz M, Rodig S, Santagata S, Garber JE, Tung N, Yélamos J, Thaxton JE, Mittendorf EA, Sorger PK, Shapiro GI, Guerriero JL.
    • Nat Cancer. 2020 Dec 14:1-2. doi: 10.1038/s43018-020-00148-7. Epub ahead of print.

    Research news: PARP Inhibitor Breast Cancer Treatments May Be Improved by Targeting Immunosuppressive Macrophages (Clinical OMICs)